CRBP

Stock Performance and Analyst Predictions: Corbus Pharmaceuticals (CRBP) closed at $6.03, with a mean price target of $52.11 suggesting a potential upside of 764.2%. Analysts show strong agreement on the company's earnings prospects, which could indicate further stock growth.

Caution on Price Targets: While analysts' price targets can provide insight, they are often overly optimistic due to business incentives. Investors should treat these targets with skepticism and consider other factors, such as earnings estimate revisions, for more reliable investment decisions.

CRB-913 Development: Corbus Pharmaceuticals has initiated a Phase 1 trial for CRB-913, a second-generation CB1 receptor inverse agonist aimed at treating obesity, which is expected to be completed by Q3 2025, with further studies planned through 2026.

Clinical Advantages: Pre-clinical data suggests that CRB-913 is significantly more peripherally restricted than previous drugs in its class, potentially reducing the risk of neuropsychiatric side effects associated with earlier treatments like rimonabant.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Analyst Ratings: Analysts have expressed bullish sentiments on Lineage Therap, Corbus Pharmaceuticals, and Tenaya Therapeutics, with all three companies receiving "Buy" ratings and significant upside potential in their price targets.

Market Performance: Despite current low share prices for these companies, the analyst consensus indicates strong buy recommendations, suggesting optimism about future growth and recovery in the healthcare sector.

Analyst Ratings: RBC Capital analyst Brian Abrahams has maintained a Buy rating on Corbus Pharmaceuticals with a price target of $65.00, while the current analyst consensus is a Strong Buy with an average price target of $57.29.

Insider Activity: There is negative sentiment among corporate insiders regarding Corbus Pharmaceuticals, as evidenced by increased selling activity, including a notable sale by CMO Dominic Smethurst earlier this month.

Analyst Rating: William Blair analyst Andy Hsieh maintains a Buy rating on Corbus Pharmaceuticals, with the stock currently priced at $7.10 and a Strong Buy consensus rating from analysts suggesting an average price target of $57.29.

Insider Activity: Recent insider activity indicates negative sentiment towards the stock, as 21 insiders have sold shares, including CMO Dominic Smethurst who sold over 6,000 shares earlier this month.

Price Target Adjustment: Jefferies has reduced the price target for Corbus Pharmaceuticals (CRBP) from $70 to $53 while maintaining a Buy rating, citing lowered peak sales forecasts for CRB-913 from $1.7B to $1.2B.

Upcoming Study Milestones: The first patient in the CRB-913 obesity study is expected to be dosed by the end of March, with data from the dose-ranging study anticipated in the first half of 2026.

ARS Pharmaceuticals Outlook: Analysts are optimistic about ARS Pharmaceuticals, maintaining a Buy rating with a strong consensus and a price target of $33.75, significantly higher than its current share price of $10.87.

Corbus Pharmaceuticals Potential: Corbus Pharmaceuticals also received a Buy rating from analysts, with a consensus price target of $57.29, indicating a potential upside of 743.7% from its recent closing price of $6.84.

Analyst Ratings: Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $42.00, while the current analyst consensus is a Strong Buy with an average price target of $58.00, indicating significant upside potential.

Company Performance: Corbus Pharmaceuticals has a market cap of $103.6M and a P/E ratio of -1.81, reflecting its current financial status amidst ongoing clinical trials and research developments.

Clinical Study Results: Corbus Pharmaceuticals presented data from their Phase 1 dose escalation study of CRB-701 at the ASCO Genitourinary Cancers Symposium, showing it was well tolerated with no dose-limiting toxicities and promising efficacy in various tumor types, including metastatic urothelial cancer.

Market Impact: Following the announcement, CRBP stock experienced a decline of 8.23%, trading at $8.70.

Stock Performance: Corbus Pharmaceuticals' shares dropped approximately 12% in premarket trading following the announcement of data from its Phase 1 clinical trial for CRB-701, an antibody drug conjugate targeting nectin-4.

Clinical Trial Results: The trial showed that CRB-701 was well tolerated with low incidence of adverse effects, and demonstrated clinical responses in patients with urothelial and cervical cancer, including one complete remission.

Clinical Study Announcement: Corbus Pharmaceuticals has released an abstract for its first-in-human dose escalation clinical study of CRB-701, targeting advanced solid tumors with high Nectin-4 expression, which will be presented at the ASCO GU symposium in February 2025.

About CRB-701: CRB-701 is a next-generation antibody-drug conjugate designed to deliver a cytotoxic payload specifically to cancer cells expressing Nectin-4, and is part of Corbus' broader oncology and obesity-focused pipeline.

Clinical Study Announcement: Corbus Pharmaceuticals will present data from its first-in-human dose escalation study of CRB-701 at the 2025 ASCO Genitourinary Cancers Symposium, focusing on patients with advanced solid tumors expressing Nectin-4.

About CRB-701: CRB-701 is a next-generation antibody-drug conjugate targeting Nectin-4 in urothelial cancer, designed to deliver a cytotoxic payload and currently undergoing evaluation for safety and efficacy in a three-part clinical trial.

Clinical Trial Announcement: Corbus Pharmaceuticals has initiated the Phase 1 clinical study of CRB-601, a monoclonal antibody aimed at treating advanced solid tumors by targeting latent TGFβ activation.

Expert Insights: Key medical professionals emphasize the significance of this trial in understanding CRB-601's potential to enhance immune response against tumors and its implications for future immunotherapy advancements.

FDA Fast Track Designation: Corbus Pharmaceuticals has received FDA Fast Track designation for its drug CRB-701, aimed at treating relapsed or refractory metastatic cervical cancer, which is currently undergoing a Phase 1 clinical trial.

Company Overview: Corbus Pharmaceuticals focuses on oncology and obesity treatments, with a diverse pipeline that includes innovative therapies targeting specific cancer cell markers and mechanisms.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Analyst Ratings: Brian Abrahams from RBC Capital maintains a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $65.00, while Oppenheimer also reiterates a Buy rating with a $60.00 target; the analyst consensus suggests a Strong Buy with a potential upside of 271.67%.

Insider Activity and Company Overview: Positive corporate insider sentiment is noted as insiders have increased their share purchases, including a significant buy by Cormorant Asset Management; Corbus Pharmaceuticals focuses on developing therapeutics for serious inflammatory diseases, with its lead product candidate being lenabasum.

Health-care Stocks Performance: Nine health-care stocks have more than doubled in price this year, with analysts projecting over 100% upside potential for each within the next 12 months. These include companies like Jasper Therapeutics and Corbus Pharmaceuticals, which are focused on innovative treatments in biotechnology.

Analyst Insights: Analysts from multiple firms have given "buy" ratings to these stocks, highlighting their potential for significant growth, particularly in sectors such as cancer treatment, rare diseases, and chronic conditions, despite the inherent risks associated with biotechnology investments.

Cormorant Asset Management's Acquisition: On September 20, 2024, Cormorant Asset Management acquired 2,375,000 shares of Corbus Pharmaceuticals at $20.01 per share, increasing its stake to 19.73% and reflecting a strategic commitment to the biotechnology sector.

Corbus Pharmaceuticals' Market Performance: Despite the acquisition, Corbus Pharmaceuticals' stock has decreased by 8.35% from the transaction price, although it has seen a significant year-to-date increase of 189.73%, indicating volatility in the biotech market.

Analyst Ratings: Corbus Pharmaceuticals received reaffirmed buy ratings from H.C. Wainwright and Oppenheimer, with price targets of $80 and $88 respectively, despite a recent stock decline attributed to Novo Nordisk's obesity drug data.

Pipeline Potential: Analysts emphasize the strength of Corbus' diversified pipeline, particularly CRB-913 and CRB-701, suggesting that the recent stock drop is an overreaction and highlighting the unique efficacy of different drugs within the same class.